What is QurAlis?
QurAlis is a precision medicine company dedicated to conquering neurodegenerative diseases through the development of targeted therapies. Founded by a team of distinguished neurodegenerative biologists from Harvard Medical School and Harvard University, the firm utilizes unique biomarkers and proprietary platforms to design drugs that act directly on disease-causing genetic alterations. By focusing on genetically validated targets, QurAlis aims to transform the standard of care for patients suffering from ALS and other complex neurological disorders, positioning itself as a leader in the next generation of therapeutic innovation.
How much funding has QurAlis raised?
QurAlis has raised a total of $150M across 3 funding rounds:
Series A
$42M
Series B
$88M
Debt
$20M
Series A (2020): $42M with participation from Mitsui Global Investment, Dementia Discovery Fund, Sanford Biosciences, Droia Ventures, MP Healthcare Venture Management, LS Polaris Innovation Fund, Amgen Business Development, Dolby Family Ventures, Mission BioCapital, and INKEF Capital
Series B (2023): $88M led by Sanofi Ventures
Debt (2025): $20M, investors not publicly disclosed
Key Investors in QurAlis
Mitsui Global Investment
Mitsui & Co. Global Investment, Inc. specializes in guiding innovative entrepreneurs by providing not just financial support but also strategic guidance to help them reach the global stage.
MP Healthcare Venture Management
MP Healthcare Venture Management is a Boston-based life science venture capital firm that collaborates with healthcare entrepreneurs to develop novel technologies and therapeutics.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with innovative ideas and transformative new products.
What's next for QurAlis?
With the recent influx of capital, QurAlis is poised to scale its research and development efforts, focusing on the clinical validation of its lead candidates. The strategic deployment of these funds will likely prioritize the expansion of its pipeline and the acceleration of its clinical trial programs. As the company moves forward, the focus will remain on translating its scientific breakthroughs into tangible patient outcomes, while maintaining its competitive edge in the rapidly evolving biotech landscape. The firm's ability to attract top-tier institutional backing suggests a robust outlook for its upcoming milestones and potential future partnerships.
See full QurAlis company page
